MYB and chronic myelogenous leukemia, BCR-ABL1 positive: MYB was approximately two-fold upregulated in imatinib-resistant BCR/ABL1-positive KCL-22R CML cells compared with sensitive cells as part of an oncogenic myeloid differentiation-blocking network comprising MYC/miR-150/MYB/miR-155/PU-1.